Inventor
James A. Johnson
Inventor
Pennington, NJ, US
Overview
Patents· 52 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds34%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
A61KPreparations for medical, dental or toiletry purposes13%
C07CAcyclic or carbocyclic compounds8%
C04BLime, magnesia4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
C07BGeneral methods of organic chemistry1%
A61LMethods or apparatus for sterilising materials or objects in general1%
A61MDevices for introducing media into, or onto, the body1%
G06QInformation and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes1%
PatentTitleYear
11,045,622Shoulder-worn diffuser202111,010,834System and method for optimizing execution of trading orders202110,977,904System and method for wagering based on multiple financial market indicators202110,676,460Quinazolines as potassium ion channel inhibitors202010,590,1136-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists202010,392,3472,4-dihydroxy-nicotinamides as APJ agonists201910,336,7394-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists201910,287,299Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity201910,202,405Fused pentacyclic imidazole derivatives201910,173,991Sulfone amide linked benzothiazole inhibitors of endothelial lipase201910,106,5286-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists201810,011,5944-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists20189,969,728Tetrahydroimidazopyridine derivatives as modulators of TNF activity20189,822,096'Quinazolines as potassium ion channel inhibitors'20179,550,737'TNF -α modulating benzimidazoles'20179,458,114'Quinazolines as potassium ion channel inhibitors'20169,309,243'Imidazopyridine derivatives as modulators of TNF activity'20169,174,974'Macrocyclic factor VIIa inhibitors'20159,169,240'Ketone linked benzothiazole inhibitors of endothelial lipase'20159,102,599'N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases'20158,987,314'Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase'20158,921,542'Epothilone derivatives'20148,680,090'Sulfonyl containing benzothiazole inhibitors of endothelial lipase'20148,642,576'Heterocyclic CETP inhibitors'20148,637,491'Thieno-pyridine derivatives as MEK inhibitors'20148,604,051'Thieno-pyridine derivatives as MEK inhibitors'20138,575,184'Quinazolines as potassium ion channel inhibitors'20138,536,327'Epothilone derivatives'20138,404,896'N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases'20138,394,822'Thieno-pyridine derivatives as MEK inhibitors'20138,357,704'Fused heterocyclic compounds as inhibitors of potassium channel function'20138,357,809'Acyclic IKur inhibitors'20138,350,037'Thieno-pyridine derivatives as MEK inhibitors'20138,304,403'Heterocyclic CETP inhibitors'20128,283,359'Thieno-pyridine derivatives as MEK inhibitors'2012RE043003'Epothilone derivatives'20117,915,410'Acyclic IKur inhibitors'20117,888,376'Heterocyclic CETP inhibitors'2011RE041893'Epothilone derivatives'2010RE041895'Epothilone derivatives'20107,790,770'Heterocyclic CETP inhibitors'20107,786,177'Phenylalanine enamide derivatives'20107,772,232'Quinazolinyl compounds as inhibitors of potassium channel function'20107,645,770'Phenylalanine enamide derivatives'20107,531,549'Phenylalanine enamide derivatives'20097,501,437'Phenylalanine enamide derivatives'20097,241,755'Epothilone derivatives'20077,125,899'Epothilone derivatives'20067,122,556'Phenylalanine enamide derivatives'20066,878,718'Phenylalanine enamide derivatives'20056,605,599'Epothilone derivatives'20036,320,045'Process for the reduction of oxiranyl epothilones to olefinic epothilones'2001Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2001–2020Patents assigned to BRISTOL MYERS SQUIBB CO (33)· patent assignee history
2001–2013Based in Lawrenceville, NJ, US· patent location history
2005–2013Based in Berkshire, GB· patent location history
2006–2019Based in Slough, GB· patent location history
2009–2014Patents assigned to UCB PHARMA SA (9)· patent assignee history
2010–2020Based in Pennington, NJ, US· patent location history
2011–2014Patents assigned to JOHNSON JAMES A (8)· patent assignee history
2012–2014Patents assigned to LLOYD JOHN (5)· patent assignee history
2016–2019Patents assigned to UCB BIOPHARMA SPRL (5)· patent assignee history
2021Based in Little Rock, AR, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BRISTOL MYERS SQUIBB CO | 33 | 2001–2020 |
| UCB PHARMA SA | 9 | 2009–2014 |
| JOHNSON JAMES Aself | 8 | 2011–2014 |
| LLOYD JOHN | 5 | 2012–2014 |
| UCB BIOPHARMA SPRL | 5 | 2016–2019 |
Locations
| Location | Patents | Span |
|---|---|---|
| Pennington, New Jersey, US | 25 | 2010–2020 |
| Slough, GB | 10 | 2006–2019 |
| Lawrenceville, New Jersey, US | 8 | 2001–2013 |
| Berkshire, GB | 6 | 2005–2013 |
| Little Rock, AR, US | 1 | 2021 |